These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6388012)

  • 1. A double-blind trial of ticlopidine in sickle cell disease.
    Semple MJ; Al-Hasani SF; Kioy P; Savidge GF
    Thromb Haemost; 1984 Jul; 51(3):303-6. PubMed ID: 6388012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
    Knudsen JB; Kjøller E; Skagen K; Gormsen J
    Thromb Haemost; 1985 Jun; 53(3):332-6. PubMed ID: 3901391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises.
    Cabannes R; Lonsdorfer J; Castaigne JP; Ondo A; Plassard A; Zohoun I
    Agents Actions Suppl; 1984; 15():199-212. PubMed ID: 6385647
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids.
    Tomer A; Kasey S; Connor WE; Clark S; Harker LA; Eckman JR
    Thromb Haemost; 2001 Jun; 85(6):966-74. PubMed ID: 11434703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of ticlopidine on cardiopulmonary function of sickle cell patients not in crisis.
    Lonsdorfer J; Castaigne JP; Lenormand E; Otayeck A; Bogui P; Dosso Y; Cabannes R
    Agents Actions Suppl; 1984; 15():213-8. PubMed ID: 6592944
    [No Abstract]   [Full Text] [Related]  

  • 6. A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
    Nyberg G; Larsson O; Westberg NG; Aurell M; Jagenburg R; Blohmé G
    Clin Nephrol; 1984 Mar; 21(3):184-7. PubMed ID: 6705280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet release proteins in plasma in peripheral arterial obliterative disease during ticlopidine administration].
    Klingemann HG; Egbring R
    Dtsch Med Wochenschr; 1982 Sep; 107(37):1388-91. PubMed ID: 7117151
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview: clinical experiences with ticlopidine.
    Day HJ
    Agents Actions Suppl; 1984; 15():297-309. PubMed ID: 6385654
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters].
    Kohriyama T; Tanaka E; Katayama S; Yamamura Y; Nakamura S
    Rinsho Shinkeigaku; 1994 Aug; 34(8):771-6. PubMed ID: 7994982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
    Verstraete M
    Agents Actions Suppl; 1984; 15():173-87. PubMed ID: 6091423
    [No Abstract]   [Full Text] [Related]  

  • 11. [Abnormalities of blood coagulation and effect of anticoagulant therapy in postoperative patients with lung cancer].
    Ogawa J; Tsurumi T; Inoue H; Inoue H; Koide S; Kawada S; Shohtsu A
    Nihon Geka Gakkai Zasshi; 1986 Jun; 87(6):697-703. PubMed ID: 2942757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted platelet proteins with antiheparin and mitogenic activities in chronic renal failure.
    Guzzo J; Niewiarowski S; Musial J; Bastl C; Grossman RA; Rao AK; Berman I; Paul D
    J Lab Clin Med; 1980 Jul; 96(1):102-13. PubMed ID: 6446588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of ticlopidine on peripheral obliterating arteriopathy].
    Stiegler H; Hess H; Mietaschk A; Trampisch HJ; Ingrisch H
    Dtsch Med Wochenschr; 1984 Aug; 109(33):1240-3. PubMed ID: 6381015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombogenesis in sickle cell disease.
    Tomer A; Harker LA; Kasey S; Eckman JR
    J Lab Clin Med; 2001 Jun; 137(6):398-407. PubMed ID: 11385360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension.
    Ding YA; Chou TC; Lin KC
    J Hum Hypertens; 1994 Apr; 8(4):273-8. PubMed ID: 8021907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
    Mellouli F; Bejaoui M
    Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.
    Tohgi H
    Agents Actions Suppl; 1984; 15():279-82. PubMed ID: 6385652
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study.
    Koc A; Gumruk F; Gurgey A
    Pediatr Hematol Oncol; 2003 Sep; 20(6):429-34. PubMed ID: 14631615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet and coagulation function in patients with abnormal cardiac valves treated with sulphinpyrazone.
    Ludlam CA; Allan N; Blandford RB; Dowdle R; Bentley NJ; Bloom AL
    Thromb Haemost; 1981 Dec; 46(4):743-6. PubMed ID: 6460338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.
    Tang YD; Rinder HM; Katz SD
    Am Heart J; 2007 Sep; 154(3):494.e1-7. PubMed ID: 17719296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.